|
Product Information |
|
Product name |
Linaclotide |
|
CAS No. |
851199-59-2 |
|
Molecular Formula |
C59H79N15O21S6 |
|
Molecular Weight |
1526.736 g/mol |
|
Quality Standard |
98% up, Medicine Grade |
|
Appearance |
White powder |
|
Sequence |
H-Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH cyclic(1-6),(2-10),(5-13)-tris(disulfide) |
|
COA of Linaclotide |
|
Test |
Specifications |
|
Appearance |
White or almost white crystalline powder |
|
Identity by HPLC |
The reaction is same with the reference substance |
|
Amino Acid Composition |
±20% of theoretical |
|
Purity (HPLC) |
≥ 98.0% |
|
Related Substance(By HPLC) |
Total Impurities(%)≤ 2.0% |
|
Acetate Content(By HPLC) |
≤15% |
|
Water Content(By HPLC) |
≤5.0% |
|
Bacterial Endotoxins |
≤5IU/mg |
|
Usage |
Function of Linaclotide
Linaclotide can bind to the guanylate cyclase C-type receptor (GC-C) in the intestinal tract after being taken orally into the human body to increase the intracellular and extracellular cyclic guanylic acid (cGMP) concentration and stimulate the secretion of intestinal juice , To accelerate the migration of the gastrointestinal tract, thereby increasing the frequency of bowel movements. Due to its unique mechanism of action, it is promising to become a therapeutic drug that can not only treat constipation, but also treat abdominal distension, abdominal pain and other clinical symptoms.
Gold supplier
Facebook 
Twitter 
Linkedin 
YouTube 
Blogger 
Instagram 
